Find comprehensive information on Metastatic Renal Cell Carcinoma, including clinical documentation, medical coding (ICD-10 C64, C79.0), staging (TNM), treatment options, and prognosis. This resource offers guidance for healthcare professionals on accurate diagnosis, coding best practices, and managing mRCC in patient care. Learn about symptoms, diagnostic criteria, and the latest research related to metastatic kidney cancer.
Also known as
Malignant neoplasm of kidney
Cancers specifically affecting the kidney, including renal cell carcinoma.
Secondary malignant neoplasm of lymphoid tissue
Cancers that have spread to lymph nodes, a common site for renal cell carcinoma metastasis.
Secondary malignant neoplasm of lung
Specifically indicates metastasis to the lungs, a frequent site for renal cell carcinoma spread.
Secondary malignant neoplasm of bone and bone marrow
Indicates spread to bone, another possible site of distant metastasis in renal cell carcinoma.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the renal cell carcinoma primary?
When to use each related code
| Description |
|---|
| Metastatic Renal Cell Carcinoma |
| Renal Cell Carcinoma |
| Kidney Cyst |
Incorrect coding of right, left, or unspecified laterality for the primary kidney tumor can impact staging and treatment data.
Lack of specific coding for all metastatic sites (e.g., bone, lung) can lead to inaccurate reporting and affect quality metrics.
Incorrect sequencing of primary and secondary malignancy codes (C64.9, C79.--) can impact reimbursement and cancer registry data.
Q: What are the most effective first-line systemic therapy options for clear cell metastatic renal cell carcinoma (mccRCC) in the era of immunotherapy and targeted therapy combinations?
A: Current guidelines recommend combination therapies as first-line treatment for most patients with clear cell metastatic renal cell carcinoma (mccRCC) who have intermediate or poor-risk disease. Specifically, combinations of immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors (TKIs), or two ICIs together, have demonstrated superior efficacy compared to TKI monotherapy in terms of progression-free survival and overall survival. The choice between specific combinations should be individualized based on patient factors such as comorbidities, IMDC risk group, and potential drug interactions. Explore how the latest clinical trial data compare different combination regimens and inform treatment selection for mccRCC. Consider implementing a shared decision-making approach with patients to tailor therapy to their individual needs and preferences.
Q: How can I accurately differentiate between cystic renal masses and potentially metastatic renal cell carcinoma (mRCC) on imaging, and what are the recommended follow-up protocols for indeterminate renal lesions?
A: Differentiating cystic renal masses from potentially metastatic renal cell carcinoma (mRCC) requires a multi-modal approach including careful evaluation of imaging characteristics on CT and MRI. Features such as wall thickness, enhancement patterns, presence of solid components, and septations can help distinguish benign cysts from malignant lesions. The Bosniak classification system provides a framework for categorizing cystic renal masses based on their complexity and associated malignancy risk. For indeterminate renal lesions, follow-up imaging at specific intervals is crucial to monitor for any changes suggesting malignancy. Learn more about the Bosniak classification system and the recommended imaging follow-up protocols for different categories of cystic renal masses to ensure accurate diagnosis and timely management.
Patient presents with signs and symptoms suggestive of metastatic renal cell carcinoma (mRCC). Presenting complaints include [Insert specific patient complaints e.g., flank pain, hematuria, palpable abdominal mass, weight loss, fatigue, bone pain, cough, dyspnea]. Physical examination revealed [Insert pertinent positive and negative findings e.g., palpable renal mass, tenderness in the costovertebral angle, lymphadenopathy, hepatomegaly]. Patient history includes [Insert relevant medical, surgical, family, and social history including risk factors for RCC such as smoking, hypertension, obesity, family history of renal cancer, exposure to certain chemicals]. Imaging studies, including [Specify imaging modality e.g., CT abdomen and pelvis with contrast, chest X-ray, bone scan, MRI], demonstrate [Describe imaging findings e.g., a heterogeneously enhancing renal mass measuring [size] cm, with evidence of metastatic spread to [Specify metastatic sites e.g., lung, bone, liver, lymph nodes]]. Laboratory results show [Insert relevant lab values including creatinine, hemoglobin, corrected calcium, alkaline phosphatase, liver function tests]. Based on clinical presentation, imaging findings, and laboratory data, the diagnosis of metastatic renal cell carcinoma (mRCC), International Classification of Diseases (ICD) code C64, is established. Differential diagnosis includes [List relevant differential diagnoses e.g., renal cyst, renal adenoma, oncocytoma, transitional cell carcinoma]. Treatment plan includes discussion of systemic therapy options such as targeted therapy (e.g., tyrosine kinase inhibitors, mTOR inhibitors) and immunotherapy, consideration of cytoreductive nephrectomy, palliative care for symptom management, and referral to oncology and other specialists as indicated. Patient education provided regarding diagnosis, prognosis, treatment options, potential side effects, and follow-up care. Further diagnostic workup may include biopsy for histopathological confirmation and molecular profiling to guide targeted therapy selection.